Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer.
hypercholesterolemia
metastasis
prostate cancer
Journal
American journal of men's health
ISSN: 1557-9891
Titre abrégé: Am J Mens Health
Pays: United States
ID NLM: 101287723
Informations de publication
Date de publication:
Historique:
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
9
6
2021
Statut:
ppublish
Résumé
Metabolic syndrome is reported to play a role in the genesis and development not only of angina, arteriosclerosis, diabetes, and osteoporosis but also of prostate cancer. Hypercholesterolemia is a strong risk factor in prostate cancer development. The current study was conducted to analyze whether pretreatment serum levels of cholesterol correlate with prostate cancer metastasis. Three hundred fifty-one subjects who received a histopathological diagnosis of prostate cancer were evaluated by clinical factors such as age, body mass index (BMI), disease stage, Gleason score, prostate-specific antigen (PSA), total cholesterol, Luteinizing hormone (LH), testosterone, and free testosterone. A multivariate analysis was performed on these factors, and a statistically significant difference was identified in total cholesterol level (
Identifiants
pubmed: 32349610
doi: 10.1177/1557988320918788
pmc: PMC7233000
doi:
Substances chimiques
Testosterone
3XMK78S47O
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1557988320918788Références
Nat Rev Urol. 2017 Feb;14(2):107-119
pubmed: 27779230
Nat Genet. 2018 Feb;50(2):206-218
pubmed: 29335545
Carcinogenesis. 2017 Aug 1;38(8):806-811
pubmed: 28595267
Prostate. 2015 Dec;75(16):1877-85
pubmed: 26332663
Urology. 2008 Dec;72(6):1319-23
pubmed: 18602144
Mol Cancer Res. 2019 May;17(5):1166-1179
pubmed: 30808729
Curr Opin Urol. 2014 May;24(3):318-23
pubmed: 24625429
Oncotarget. 2017 Jul 18;8(29):47110-47120
pubmed: 28445145
Prostate Int. 2014 Sep;2(3):105-13
pubmed: 25325021
Prostate Cancer Prostatic Dis. 2018 Jun;21(2):252-259
pubmed: 29282360
Can J Urol. 2008 Feb;15(1):3866-71
pubmed: 18304396
Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i70-75
pubmed: 20870924
Curr Opin Pharmacol. 2012 Dec;12(6):751-9
pubmed: 22824430
Eur Urol. 2013 May;63(5):810-20
pubmed: 23219353
Korean J Urol. 2012 Oct;53(10):665-72
pubmed: 23136625
PLoS One. 2010 Dec 03;5(12):e14175
pubmed: 21151972